Physician profile
Nirav S Shah
NPI 1992968457
$8,250.58
in general payments reported to CMS, 2019-2025
17 companies · $518 in 2025
The $518 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $811 · 2020: $566 · 2021: $2,491 · 2022: $1,755 · 2023: $1,287 · 2024: $822 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,614 · Education: $13.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,613.80 |
| Education | $13.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,572.71 | 2020-2025 | Eterna, Proclaim |
| Janssen Pharmaceuticals, INC | $612.01 | 2022-2023 | Xarelto |
| Pfizer INC. | $486.39 | 2019 | |
| Nalu Medical, INC. | $373.60 | 2021-2023 | Nalu Neurostimulation System |
| Spr Therapeutics, INC | $194.62 | 2021 | |
| Avanos Medical | $169.39 | 2019 | |
| Nevro Corp. | $144.08 | 2019 | |
| Depuy Synthes Sales INC. | $142.01 | 2021-2023 | Motoband |
| Ferring Pharmaceuticals INC. | $129.60 | 2023 | Rebyota |
| Grt US Holding, INC. | $127.11 | 2022 | |
| Biotissue Holdings INC. | $101.42 | 2020 | |
| Boston Scientific Corporation | $91.17 | 2020 | |
| Abbvie INC. | $82.08 | 2023 | Avycaz |
| Shionogi INC | $13.20 | 2024 | Fetroja |
| Emd Serono, INC. | $11.19 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirav Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.